NEW YORK, Sept. 11, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of OvaScience, Inc. ("OvaScience" or the "Company") (NasdaqGM: OVAS). The investigation focuses on whether the Company and its executives complied with federal securities laws.
On September 11, 2013, share of OvaScience fell $3.12 during intraday trading to trade at $11.15 after the company said Tuesday after markets closed that the FDA is questioning the status of its potential fertility treatment, Augment. The FDA was questioning Augment's status as a lower-risk form of a human cellular and tissue-based product. The FDA told the company to file an investigational new drug application for the product, which would require rounds of clinical testing and could delay the treatment from reaching the U.S. market.
If you are aware of any facts relating to this investigation, or purchased shares of OvaScience, you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC